The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Zomedica Files US Provisional Patent Application for Novel Pharmaceutical Formulation

12-Jul-2016 | Source : Zomedica Pharmaceuticals | Visits : 5953
ANN ARBOR, Mich. – Zomedica Pharmaceuticals Corp., a veterinary pharmaceutical company, today announced in a press release that it has filed a provisional application for patent with the United States Patent and Trademark Office (USPTO) for a novel formulation of ZM-006, a pharmaceutical targeting a metabolic disorder in companion animals. This provisional application is based on positive results from both in-vivo and in-vitro studies designed to address the unique formulation requirements of companion animals.

Concurrently, Zomedica opened its second Investigational New Animal Drug (INAD) application with the US Food and Drug Administration Center for Veterinary Medicine for ZM-006.

“Together, these applications signify a breakthrough pertaining to the ongoing development of our pioneering drug delivery technology,” stated William MacArthur, MS, DVM, Chief Medical Officer of Zomedica. “Our R&D efforts are focused on developing solutions that support the high medical standards of veterinarians by providing products proven safe and effective and formulated for their pet patients.”

“This is a pivotal step in cultivating what is becoming a robust intellectual property portfolio,” stated Zomedica President and CEO Gerald Solensky, Jr. “Our goal is to ensure Zomedica’s long-term commercial position by continuing to meet disclosed milestones and shareholder expectations.”

Related Articles